Abstract
Methods Data were retrospectively collected from patients eligible for the ETV expanded access program. Individuals received ETV 200 mg BID plus an optimised background regimen (OBR). OBR consisted of reverse transcriptase inhibitors +/protease inhibitors +/entry/fusion inhibitors +/integrase inhibitors. Baseline patient characteristics were analysed. CD4 cell count and viral load (VL) were measured at baseline, 12, 24, 36 and 48 weeks.
Highlights
Etravirine (ETV) is a generation non-nucleoside reverse transcriptase inhibitor (NNRTI) with activity against wild-type and NNRTI-resistant HIV-1
We present our experience with ETV from the Chelsea & Westminster cohort nucleoside analogues. 48% of patients had one or more NNRTI resistance associated mutations (RAMs)
44 patients switched with an undetectable viral load (VL). 37% patients had ≥1 NNRTI RAMs
Summary
Address: Chelsea & Westminster Hospital NHS Foundation Trust, London, UK * Corresponding author from Ninth International Congress on Drug Therapy in HIV Infection Glasgow, UK. 9–13 November 2008. Address: Chelsea & Westminster Hospital NHS Foundation Trust, London, UK * Corresponding author from Ninth International Congress on Drug Therapy in HIV Infection Glasgow, UK. Published: 10 November 2008 Journal of the International AIDS Society 2008, 11(Suppl 1):P49 doi:10.1186/1758-2652-11-S1-P49. Abstracts of the Ninth International Congress on Drug Therapy in HIV Infection Meeting abstracts – A single PDF containing all abstracts in this Supplement is available here. http://www.biomedcentral.com/content/pdf/1758-2652-11-S1-info.pdf
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
